Virtu Financial’s Regulus Therapeutics RGLS Stock Holding History

Virtu Financial’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-25,921	Closed	-$36K	–	1934
2023 Q3	$36K	Buy	+25,921	New	+$37.6K	﹤0.01%	939
2022 Q3	–	Sell	-10,205	Closed	-$21K	–	2149
2022 Q2	$21K	Buy	+10,205	New	+$24.8K	﹤0.01%	1321
2021 Q3	–	Sell	-7,919	Closed	-$64K	–	1885
2021 Q2	$64K	Buy	+7,919	New	+$88.4K	0.01%	1291
2020 Q3	–	Sell	-8,435	Closed	-$57K	–	1435
2020 Q2	$57K	Buy	+8,435	New	+$55.2K	0.01%	988
2019 Q4	–	Sell	-1,690	Closed	-$12K	–	1778
2019 Q3	$12K	Buy	+1,690	New	+$13.8K	﹤0.01%	1334
2019 Q2	–	Sell	-6,659	Closed	-$68K	–	1785
2019 Q1	$68K	Buy	+6,659	New	+$72.4K	﹤0.01%	1179
2018 Q2	–	Sell	-655	Closed	-$56K	–	2420
2018 Q1	$56K	Buy	+655	New	+$87.6K	﹤0.01%	1693

Other funds holding RGLS

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

EAM

Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial's RGLS Position: Q4 2023 in Review

Virtu Financial sold out of Regulus Therapeutics (RGLS) in Q4 2023, closing a stake of 25,921 shares — an estimated $36K sold.

Virtu Financial first reported a position in RGLS in Q1 2018 and held it in 7 quarters. The position peaked at $68K in Q1 2019. 26 funds tracked by Wall St. Rank hold RGLS as of Q4 2023.

Virtu Financial reported no remaining Regulus Therapeutics position as of Q4 2023 after selling out during the quarter.
Virtu Financial sold 25,921 Regulus Therapeutics shares in Q4 2023, an estimated $36K.
Virtu Financial first reported a position in Regulus Therapeutics in Q1 2018 and held it in 7 quarters.
Virtu Financial's Regulus Therapeutics position peaked at $68K in Q1 2019.
26 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2023.

Based on Virtu Financial's 13F filing for Q4 2023, filed 26 Feb 2024.